FDA Sends Five Warning Letters to Online Peptide Sellers, Rejecting 'Research Use Only' Labels on Injectable Peptides

The FDA has opened a new front in its oversight of the online peptide market. In five warning letters dated August 24, 2026, and made public on September 1, the agency's drug center told a group of internet sellers that their products are unapproved new drugs, and it refused to treat the familiar 'research use only' label as a shield. The action targets the exact channel that has fed a fast-growing gray market for injectable peptides, and it lays out a legal theory that reaches well beyond the five named companies. This is general information, not medical or legal advice.

What the FDA did

The FDA's Center for Drug Evaluation and Research (CDER) sent warning letters to Peak Performance Peptides, Royal Peptides LLC, NuScience Peptides LLC, Peptide Partners LLC, and TXP Innovations LLC, which does business as Tex Peptides. Each letter is dated August 24, 2026, and the agency posted them on its public warning-letter database on September 1. In every case the FDA alleges the seller introduced unapproved new drugs into interstate commerce and gave the company 15 business days to respond in writing.

A warning letter is the FDA's formal notice of alleged violations found during a review, not a final court judgment. It asks the recipient to correct the problems and reply, and the company can remediate or contest the agency's position. The letters describe alleged conduct; they do not establish that a court has found any violation.

The 'research use only' label did not shield the sellers

Each site had marked its products 'research use only' or 'not for human use,' the disclaimer the peptide trade has long relied on to argue the vials are laboratory chemicals rather than drugs. The FDA rejected that framing. Reviewing each website as a whole, the agency concluded the disclaimers were contradicted by the surrounding content. As the letters put it, 'despite statements on your product labeling marketing your products for research use only,' the evidence from the website 'establishes that your products are intended to be drugs for human use.'

The agency applied a net-impression, intended-use standard: disease and body-composition claims, human dosing guidance, peptide reconstitution calculators, and bacteriostatic water sold alongside the vials all pointed to human use. Under that reading, a label saying 'not for human use' does not control when the rest of the storefront is built to help a person inject the product.

Which peptides the letters name

The products cited across the five letters span metabolic, recovery, and sexual-health categories. Named substances include:

• GLP-1 class and related metabolic peptides: semaglutide, tirzepatide, retatrutide, survodutide, and mazdutide.
• Mitochondrial and recovery peptides: SS-31 (elamipretide) and tesamorelin, a growth-hormone-releasing peptide.
• Sexual-health peptide: PT-141, also known as bremelanotide.

Several of these are the active ingredients in FDA-approved prescription medicines when made by an approved manufacturer. Semaglutide and tirzepatide, for example, are approved as branded injectables for diabetes and weight management. Sold as loose vials by an online peptide seller with no approved application, the FDA treats them as unapproved new drugs regardless of the molecule's status inside an approved product.

Bacteriostatic water and the injection question

One recurring detail across the letters is bacteriostatic water, the sterile diluent used to reconstitute a lyophilized peptide before injection. For sellers such as NuScience and Peptide Partners, the FDA said offering that diluent next to the peptides, together with a calculator that 'provides the means to prepare an injectable drug for human administration,' helped answer the intended-use question. In the agency's view, bundling the vial, the mixing water, and the dosing math describes a product meant to be injected by a person, not studied on a lab bench.

The legal basis the FDA cites

The letters rest on core provisions of the Federal Food, Drug, and Cosmetic Act. The FDA points to Section 201(g)(1), which defines a drug in part by its intended use, and Section 201(p), which defines a new drug. Because none of the products has an approved application, the agency alleges the sales violate Section 505(a) and the prohibition in Section 301(d) on introducing an unapproved new drug into interstate commerce. Some letters also flag misbranding. These are the agency's allegations under the statute, and the recipients have the chance to respond before any further step.

What this means for the online peptide market

The significance is the method, not just the five names. By reading intended use from the whole website, the FDA signaled that the 'research use only' business model does not sit outside drug law when the storefront is plainly built for human dosing. That reasoning applies to any vendor using the same playbook, which is why compliance lawyers have framed the sweep as a warning to the broader research-use-only peptide sector. The action also runs parallel to the FDA's compounding-side scrutiny of peptides, where an advisory panel reviewed whether popular peptides should remain eligible for pharmacy compounding. Buyers who lose informal supply routes may look toward licensed clinicians and pharmacies, or toward the telehealth peptide providers that operate inside the regulated system.

What buyers and clinicians should know

This is general information, not medical or legal advice. A few points follow from the record:

• A 'research use only' or 'not for human use' label does not mean a product is FDA-cleared for people, and the FDA has now said such labels do not by themselves keep a seller outside drug law.
• Products sold this way are not reviewed by the FDA for safety, purity, or dosing, and injecting an unapproved product carries risks the agency has repeatedly flagged.
• Where an approved medicine exists for a goal, such as GLP-1 drugs for weight management, a licensed clinician can explain regulated options and monitoring.
• Anyone evaluating a provider can ask how products are sourced and tested and whether a certificate of analysis exists for each batch.

What is still unsettled

The letters are a first enforcement step, not the last word. Each company can respond within 15 business days, correct the alleged violations, or dispute the agency's reading, and the FDA has not announced fines, seizures, or a court case tied to this batch. The action does not change the separate question of which peptides may be compounded at a licensed pharmacy, and it does not by itself remove any product from the market. What it does settle, for now, is the agency's position that a research-use disclaimer will not decide the question when a website is built to sell an injectable drug for human use.